AI Tool to Spot Memory Problems in People With Type 2 Diabetes
Tests an AI screening tool for early memory decline in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
Key facts
- Where
- Enshi, Huanggang, Huangshi, Jingzhou, Shiyan, Suizhou, Wuhan, Xiangyang, Xianning, Xiantao, Xiaogan, and Yichang, ChinaSee the 21 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07128186, who can take part
Where in China
- Minda Hospital Affiliated to Hubei Minzu UniversityEnshi, ChinaTaking people
- Huanggang Central HospitalHuanggang, ChinaTaking people
- Huangshi Central HospitalHuangshi, ChinaTaking people
- Jingzhou Central HospitalJingzhou, ChinaTaking people
- Sinopharm Dongfeng General HospitalShiyan, ChinaNot yet recruiting
- Suizhou Central HospitalSuizhou, ChinaNot yet recruiting
- China Resources WISCO General HospitalWuhan, ChinaTaking people
- Hubei Provincial Hospital of Integrated Chinese & Western MedicineWuhan, ChinaTaking people
- Tianyou Hospital Affiliated to Wuhan University of Science and TechnologyWuhan, ChinaNot yet recruiting
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
- Wuhan Central HospitalWuhan, ChinaTaking people
- Wuhan Fifth HospitalWuhan, ChinaTaking people
- Wuhan Fourth HospitalWuhan, ChinaTaking people
- Xiangyang Central HospitalXiangyang, ChinaNot yet recruiting
- Xiangyang First People's HospitalXiangyang, ChinaTaking people
- Xianning Central HospitalXianning, ChinaTaking people
- Xiantao First People's HospitalXiantao, ChinaNot yet recruiting
- Xiaogan Central HospitalXiaogan, ChinaTaking people
- Renhe Hospital Affiliated to China Three Gorges UniversityYichang, ChinaTaking people
- Sinopharm Gezhouba Central HospitalYichang, ChinaNot yet recruiting
- Yichang Central People's HospitalYichang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tongji Hospital
- Trial code
- NCT07128186
- Record updated
- 17 August 2025
- Original description
The objective of this observational study is to evaluate the accuracy and feasibility of an artificial intelligence-based multimodal cognitive screening system in early identification of diabetes-related mild cognitive impairment (MCI) among type 2 diabetes mellitus (T2DM) patients through a 3-5 year follow-up. It also aims to analyze the correlation between diabetic metabolic indicators (such as glycemic variability and HbA1c levels) and cognitive function changes, thereby determining the value of this intelligent screening system in early detection and intervention of cognitive impairment in T2DM patients, which constitutes the key focus of this research.Read full original descriptionShow less
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
The objective of this observational study is to evaluate the accuracy and feasibility of an artificial intelligence-based multimodal cognitive screening system in early identification of diabetes-related mild cognitive impairment (MCI) among type 2 diabetes mellitus (T2DM) patients through a 3-5 year follow-up. It also aims to analyze the correlation between diabetic metabolic indicators (such as glycemic variability and HbA1c levels) and cognitive function changes, thereby determining the value of this intelligent screening system in early detection and intervention of cognitive impairment in T2DM patients, which constitutes the key focus of this research.
Inclusion: Diagnosed with type 2 diabetes mellitus (T2DM); Aged 40-75 years, with self-reported or informant-reported memory complaints; Cognitive assessment scores consistent with either:; Cognitive Normal (CN) or; Mild Cognitive Impairment (MCI); Preserved ability to perform basic activities of daily living (ADLs); Memory-specific deficits only (e.g., partial forgetfulness), with intact other cognitive domains (e.g., reasoning, judgment, attention, and executive function).
Exclusion: Recent medication use (within 1 month):; Anti-Parkinsonian drugs, antiepileptics, sedatives/hypnotics; Cognitive-enhancing drugs (e.g., donepezil, memantine); Other types of diabetes (e.g., type 1 diabetes, gestational diabetes); Metabolic disorders that may affect cognition, including:; Acute carbohydrate metabolism events within 3 months (e.g., severe hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar state); Hypothyroidism or other endocrine disorders; Neurological/psychiatric conditions that may impair cognition:; History of head trauma, depression, anxiety, delirium, severe pulmonary/renal disease, heart failure, or malignancy; Education level <6 years; Substance abuse (past 2 years), including nicotine/alcohol dependence; Inability to complete AI screening or follow-up due to:; Speech/hearing/visual impairments or other disabilities.